Department of Radiation Oncology, The Cleveland Clinic, Cleveland, OH, United States.
Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Front Endocrinol (Lausanne). 2023 Jan 11;13:1109555. doi: 10.3389/fendo.2022.1109555. eCollection 2022.
Thyroid hormone as L-thyroxine (T4) acts nongenomically at physiological concentrations at its cancer cell surface receptor on integrin αvβ3 ('thyrointegrin') to cause cancer cell proliferation. In the case of estrogen receptor (ERα)-positive breast cancer cells, T4 the integrin promotes ERα-dependent cancer growth in the absence of estrogen. Thus, tumor growth in the post-menopausal patient with ERα-positive cancer may again be ER-dependent because of T4. Additional mechanisms by which T4 may contribute uniquely to aggressive breast cancer behavior-independently of ER-are stimulation of immune checkpoint inhibitor gene expression and of several anti-apoptosis mechanisms. These observations may call for consideration of elimination of host T4 production in breast cancer patients whose response is suboptimal to standard chemotherapy regimens. Euthyroidism in such a setting may be maintained with exogenous 3,3',5-triiodo-L-thyronine (T3).
甲状腺激素(T4)以左旋甲状腺素的形式发挥作用,在生理浓度下通过其癌细胞表面整联蛋白 αvβ3(“甲状腺整合素”)的非基因组作用,导致癌细胞增殖。在雌激素受体(ERα)阳性乳腺癌细胞中,T4 促进整合素依赖的 ERα 依赖性癌症生长,而无需雌激素。因此,绝经后 ERα 阳性癌症患者的肿瘤生长可能再次依赖于 ER,因为 T4 可能会发挥作用。T4 可能通过其他机制独特地促进侵袭性乳腺癌行为,而与 ER 无关,包括免疫检查点抑制剂基因表达和几种抗细胞凋亡机制的刺激。这些观察结果可能需要考虑消除对标准化疗方案反应不佳的乳腺癌患者的 T4 产生。在这种情况下,通过外源性 3,3',5-三碘-L-甲状腺素(T3)可维持正常甲状腺功能。